News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Subscribe To Our Newsletter & Stay Updated
